If you have been reading about TH9507 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-02. Numbers and descriptions here follow the published literature rather than marketing material.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
=== Marketing === Liraglutide was approved by the US Food and Drug Administration (FDA) in 2014, and by the European Medicines Agency (EMA) in 2015, for adults with a body mass index (BMI) of 30 or greater (obesity) or a BMI of 27 or greater (overweight) who have at least one weight-related condition. Liraglutide was approved by the FDA in 2019, for treatment of children aged ten years of age or older with type 2 diabetes, making it the first non-insulin drug approved to treat type 2 diabetes in children since metformin was approved in 2000. Novo Nordisk made deals with generic manufacturers to enter the United States market in 2024. The FDA approved the first generic liraglutide in December 2024, and granted the approval to Hikma Pharmaceuticals USA
Short bowel syndrome Small bowel obstruction Active gastrointestinal bleeding Pseudo-obstruction with complete intolerance to food High-output (defined as > 500ml/day) enteric-cutaneous fistulas (unless a feeding tube can be passed distal to the fistula) Premature birth (unable to take oral feeds)
Primary industries in Moscow include chemicals, metallurgy, food, textiles, furniture, energy production, software development, and machinery. A number of industrial organizations are located in Moscow and its surroundings. The Mil Moscow Helicopter Plant manufactures military and civil helicopters. Khrunichev State Research and Production Space Center produces space equipment, including modules for the space stations Mir, Salyut, and the International Space Station (ISS); the center also produces Proton launch vehicles and military intercontinental ballistic missiles (ICBMs). In addition, the Sukhoi, Ilyushin, Mikoyan, Tupolev, and Yakovlev bureaus design aircraft. Khimki—an independent city in Moscow Oblast that has largely been enclosed by Moscow—contains NPO Energomash, which produces rocket engines for Russian and American space programs, as well as the Lavochkin design bureau, which built fighter planes during World War II but has switched to space probes since the Space Race. Automobile plants ZiL and AZLK, as well as the Voitovich Rail Vehicle plant, are located in Moscow; the Metrovagonmash metro wagon plant is located just outside city limits. The Poljot Moscow watch factory produces military, professional, and sport watches that are known domestically and internationally. The Electrozavod factory was Russia's first transformer factory. The Kristall distillery is the oldest in Russia making vodka products, including Stolichnaya; wines are produced at Moscow plants, including the Moscow Interrepublican Winery.
There are various government and trade association regulatory bodies for acupuncture in the United Kingdom, the United States, Saudi Arabia, Australia, New Zealand, Japan, Canada, and in European countries and elsewhere. The World Health Organization recommends that an acupuncturist receive 200 hours of specialized training if they are a physician and 2,500 hours for non-physicians before being licensed or certified; many governments have adopted similar standards. In Hong Kong, the practice of acupuncture is regulated by the Chinese Medicine Council, which was formed in 1999 by the Legislative Council. It includes a licensing exam, registration, and degree courses approved by the board. Canada has acupuncture licensing programs in the provinces of British Columbia, Ontario, Alberta and Quebec; standards set by the Chinese Medicine and Acupuncture Association of Canada are used in provinces without government regulation. Regulation in the US began in the 1970s in California, which was eventually followed by every state but Wyoming and Idaho. Licensing requirements vary greatly from state to state. The needles used in acupuncture are regulated in the US by the Food and Drug Administration. In some states acupuncture is regulated by a board of medical examiners, while in others by the board of licensing, health or education. In Japan, acupuncturists are licensed by the Minister of Health, Labour and Welfare after passing an examination and graduating from a technical school or university.
Sources: en.wikipedia.org
Lagering Lagers are stored at cellar temperature or below for 1–6 months while still on the yeast. The process of storing, or conditioning, or maturing, or aging a beer at a low temperature for a long period is called "lagering", and while it is associated with lagers, the process may also be done with ales, with the same result – that of cleaning up various chemicals, acids and compounds.
=== Reports from investigative journalists === In 2003, a German investigative journalist sponsored by the British Union for the Abolition of Vivisection (BUAV) filmed 40 hours of undercover footage at the company's primate-testing facility in Münster. Two films were produced, which were shown on German public television in December 2003. The footage showed animal keepers dancing with half-anaesthetized monkeys, making their heads move to the rhythm of the music. It also showed rough treatment of the monkeys by the staff. The monkeys were seen living isolated in small wire cages with little or no natural light and no environmental enrichment, with high noise levels caused by staff shouting and playing the radio, and undergoing surgery with no post-operative care. In response, the company maintained that clips showing different technicians working in different buildings had been edited together, resulting in a sequence of events that did not take place. The company also said there was group housing and pair housing for some monkeys that was not shown. In the films, the treatment of the monkeys was criticized by Jane Goodall. The environment minister for North Rhine-Westphalia asked the public prosecutor to investigate, and said that if the allegations were borne out, the company would lose its licence to keep primates. The company gained an injunction against the video. From April 2004 to March 2005, an undercover technician, sponsored by People for the Ethical Treatment of Animals (PETA), filmed the treatment of monkeys in the company's lab in Vienna, Virginia.
The education system of Malaysia features a non-compulsory kindergarten education followed by six years of compulsory primary education and five years of optional secondary education. Schools in the primary education system are divided into two categories: national primary schools, which teach in Malay (i.e.:Sekolah Kebangsaan Sungai Binjai, SK Bukit Tiu), and vernacular schools, which teach in Chinese or Tamil (i.e.:SJK(C) Pin Hwa 2, SJK(T) Bandar Mentakab). Secondary education (i.e.:SMK Sura, Kajang High School) is conducted for five years. In the final year of secondary education, students sit for the Malaysian Certificate of Education examination. Since the introduction of the matriculation programme in 1999, students who completed the 12-month programme in matriculation colleges can enrol in local universities. However, in the matriculation system, only 10% of places are open to non-bumiputera students.
== Signs and symptoms == The characteristic features of achondrogenesis type 2 are short arms and legs, a tiny chest with short ribs, lung hypoplasia, a small chin, a prominent forehead, and an enlarged abdomen that may also include hydrops, and polyhydramnios.
== Medical uses == The primary target for the development of FIAU was the treatment of chronic hepatitis B virus (HBV) infection. FIAU is a nucleoside analogue, meaning that the molecule is similar to the building blocks of deoxyribonucleic acid, DNA. Once it enters the body and it is phosphorylated by viral thymidine kinase the FIAU is activated. The FIAU will then be incorporated into the viral DNA while the virus is dividing. The virus will begin building a new DNA strand and use FIAU as a ‘building block’, but as it is an analogue and not a real nucleotide the DNA chain cannot be completed. FIAU was a potent inhibitor of HBV replication, thus resulting in a large decrease in serum HBV DNA levels. FIAU (and its parent drug FIAC) was also studied for the use in treating herpes simplex virus (HSV), varicella zoster virus (VZV), and cytomegalovirus (CMV). Nowadays FIAU is an important compound in the field of drug-induced liver injury research. FIAU, despite its early promise, was never put on the market and has never been available for medicinal use. In the initial clinical trials FIAU was a potent inhibitor of the HBV replication, as patients experienced a large decrease in serum HBV DNA levels. And in the high-dosed groups the HBV DNA was reduced by 70 to 95%. But even though the treatment was very promising, the antiviral effect was almost always temporary.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
反相高效液相色谱用于分离和纯度评估，质谱用于分子量确认。肽图谱或串联质谱可进一步验证序列。具体方法需根据样品基质和监管要求选择。